Relmada Financial Statements From 2010 to 2026

Relmada Therapeutics Balance Sheet		Trends
Current Value Last Year Historical Average  10 Year Trend Total Assets 68.5 M 52.7 M 59.9 M Slightly volatile Total Current Liabilities 9.1 M 9.3 M 12 M Slightly volatile Accounts Payable 3 M 4.8 M 2.8 M Slightly volatile Cash 3.3 M 3.5 M 14 M Slightly volatile Cash And Short Term Investments 66.3 M 51.6 M 58.1 M Slightly volatile Common Stock Total Equity 25.7 K 27.1 K 239 K Slightly volatile Common Stock Shares Outstanding 36.4 M 34.7 M 14.5 M Slightly volatile Liabilities And Stockholders Equity 68.6 M 52.7 M 60.1 M Slightly volatile Inventory 4.9 M 4.6 M 2.3 M Slightly volatile Total Liabilities 9.3 M 9.3 M 12.2 M Slightly volatile Total Current Assets 68.2 M 52.7 M 59.7 M Slightly volatile Common Stock 23.7 K 34.7 K 23.6 K Very volatile Short and Long Term Debt Total 120.4 K 126.8 K 583.7 K Pretty Stable Other Current Liabilities 7.3 M 5.5 M 10.8 M Slightly volatile Current Deferred Revenue 1.6 M 1.5 M 893.9 K Slightly volatile Non Current Assets Total 18.8 K 19.8 K 178.3 K Pretty Stable Non Currrent Assets Other 18.8 K 19.8 K 78.6 K Pretty Stable Capital Surpluse 727.5 M 692.9 M 302 M Slightly volatile Other Stockholder Equity 816.7 M 777.8 M 306.2 M Slightly volatile Property Plant And Equipment Gross 14.3 K 15 K 41.8 K Pretty Stable Short Term Debt 218.6 K 126.8 K 153.1 K Pretty Stable Property Plant Equipment 1.1 K 1.1 K 36.6 K Pretty Stable Other Liabilities 132.5 K 162.1 K 132 K Slightly volatile Other Assets 29.8 K 31.4 K 132.1 K Pretty Stable Short and Long Term Debt 279 K 418.8 K 269.4 K Slightly volatile Net Receivables 618.8 K 589.3 K 241.4 K Slightly volatile Preferred Stock Total Equity 57.6 64.8 70.7294 Slightly volatile Non Current Liabilities Other 112.7 K 126.8 K 138.4 K Slightly volatile Long Term Investments 270.2 K 304 K 331.8 K Slightly volatile Long Term Debt 2.1 M 2.4 M 2.6 M Slightly volatile Long Term Debt Total 2.1 M 2.4 M 2.6 M Slightly volatile Capital Stock 23.1 K 27.2 K 32.5 K Slightly volatile Short Term Investments 35.1 M 36.9 M 84.2 M Very volatile
Relmada Therapeutics Income Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Depreciation And Amortization 101.3 M 96.5 M 22.7 M Slightly volatile Selling General Administrative 45.5 M 43.4 M 19.4 M Slightly volatile Selling And Marketing Expenses 16.3 M 15.5 M 7 M Slightly volatile Other Operating Expenses 52 M 96.5 M 44.9 M Slightly volatile Cost Of Revenue 1.1 K 1.1 K 11.7 K Pretty Stable Total Operating Expenses 52 M 96.5 M 44.9 M Slightly volatile Research Development 34.9 M 53.1 M 28.5 M Slightly volatile Interest Expense 5.1 M 4.8 M 1.6 M Slightly volatile Interest Income 3.1 M 4.1 M 2.1 M Slightly volatile Non Operating Income Net Other 1.2 M 1.4 M 1.5 M Slightly volatile
Relmada Therapeutics Cash Flow Statement		Trends
Current Value Last Year Historical Average  10 Year Trend Begin Period Cash Flow 4.5 M 4.7 M 10.9 M Pretty Stable End Period Cash Flow 4.2 M 4.4 M 7.6 M Very volatile Sale Purchase Of Stock 35.1 M 49.1 M 29.8 M Slightly volatile Stock Based Compensation 36.5 M 34.7 M 15.1 M Slightly volatile
Financial Ratios		Trends
Current Value Last Year Historical Average  10 Year Trend Price To Sales Ratio 4.1 K 4.3 K 12.5 K Slightly volatile Average Payables 2.6 M 3.9 M 3.8 M Slightly volatile Stock Based Compensation To Revenue 2.26 2.54 2.7729 Slightly volatile Capex To Depreciation 5.57 5.42 5.3461 Slightly volatile EV To Sales 4.1 K 4.3 K 11.3 K Slightly volatile Inventory Turnover 1.09 1.04 0.4645 Slightly volatile Days Of Inventory On Hand 345 363 21.7 K Slightly volatile Payables Turnover 1.0 0.95 0.4217 Slightly volatile Sales General And Administrative To Revenue 0.98 1.03 2.9268 Slightly volatile Average Inventory 2.6 K 2.9 K 3.1 K Slightly volatile Capex To Revenue 0.28 0.32 0.345 Slightly volatile Cash Per Share 1.27 1.34 3.7306 Pretty Stable Days Payables Outstanding 376 396 29 K Slightly volatile Income Quality 1.03 0.74 0.8331 Very volatile Current Ratio 3.8 4.0 8.9076 Pretty Stable Average Receivables 160.2 K 269.5 K 217.8 K Slightly volatile Revenue Per Share 0.0015 0.0029 0.0019 Slightly volatile Interest Debt Per Share 0.0102 0.0108 0.107 Very volatile Debt To Assets 8.0E-4 8.0E-4 0.0678 Very volatile Operating Cycle 345 363 21.7 K Slightly volatile Days Of Payables Outstanding 376 396 29 K Slightly volatile Ebt Per Ebit 0.78 0.86 1.0167 Slightly volatile Quick Ratio 3.8 4.0 8.8574 Pretty Stable Cash Ratio 0.32 0.34 2.5314 Very volatile Days Of Inventory Outstanding 345 363 21.7 K Slightly volatile Free Cash Flow Operating Cash Flow Ratio 1.13 1.15 1.0554 Slightly volatile Fixed Asset Turnover 0.42 0.47 0.5122 Slightly volatile Debt Ratio 8.0E-4 8.0E-4 0.0678 Very volatile Price Sales Ratio 4.1 K 4.3 K 12.5 K Slightly volatile Asset Turnover 0.52 0.5 0.34 Slightly volatile Gross Profit Margin 0.26 0.31 0.2582 Slightly volatile
Relmada Therapeutics Valuation Data		Trends
Current Value Last Year Historical Average  10 Year Trend Market Cap 33.4 M 23.3 M 46.4 M Very volatile

Relmada Fundamental Market Drivers

Relmada Upcoming Events

About Relmada Therapeutics Financial Statements

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Relmada Therapeutics is a strong investment it is important to analyze Relmada Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Relmada Therapeutics' future performance. For an informed investment choice regarding Relmada Stock, refer to the following important reports:

How To Invest In Relmada Details

Is Relmada Stock a good investment? Details

What is Relmada Therapeutics' Net Worth? Details

Largest Pharmaceuticals Companies View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies View

Altman Z Score Details

Piotroski F Score Details

Beneish M Score Details

Financial Analysis Details

Buy or Sell Advice Details

Earnings Projections Details